Methods: This retrospective study included patients with class II LN at their first renal biopsy between January 1996 and December 2016 in King Khaled University Hospital, Riyadh, Saudi Arabia. The rate of complete remission, worsening renal function, and histological transformation in the second biopsy were examined.
LN have excellent prognosis and outcomes compared to other classes (III, IV, and V). 3 However, there are discrepancies in the guidelines on the treatment of class II LN due to a lack of evidence. Most of the guidelines published in the National Library of Medicine recommend hydroxychloroquine alongside reninangiotensin-aldosterone system (RAAS) inhibitors to manage proteinuria. [4] [5] [6] The role of immunosuppression management in International Society of Nephrology/ Renal Pathology Society (ISN/RPS)-defined class II LN is less clear. Moreover, patients with LN class II are at higher risk of histological transformation compared to other ISN/RPS classes, 7 which might change their prognosis and disease management. [8] [9] [10] [11] The main objective of this study is to assess how patients with LN class II respond to immunosuppressive therapy, their long-term prognosis and their histological transformation to other ISN/RPS classes in a repeated biopsy.
Methods. This retrospective study includes patients who received a diagnosis of LN class II on their first renal biopsy between January 1996 and December 2016 in accordance with the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification 7 at King Khalid University Hospital in Riyadh, Saudi Arabia. All patients with diagnosis of SLE and had a native kidney biopsy were included. Only patients with incomplete records were excluded. The biopsies were re-evaluated by 2 renal pathologists blinded to the clinical data. This study retrospectively reviews medical records of patients who have been diagnosed with LN and data were recorded for standard clinical purposes. To protect confidentiality, data were analyzed and reported in a de-identified, aggregate form. The study was approved by the Institutional Review Board (IRB) at King Saud University (E-12-811) and no patient consent was collected.
Demographic, clinical and histological data were analyzed. The clinical data included the initial presentation to the nephrologist and symptoms of SLE (photosensitivity, arthritis, oral ulcers, serositis, and malar, renal, cerebral, hematological and discoid rashes). Laboratory data including urine sediments, urine protein, and complement (C3, C4), were collected at the time of diagnosis, first biopsy, 6 months after the first renal biopsy and last follow-up. The Standard Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score was used at the time of the kidney biopsy to assess the disease activity. 12 At the first renal biopsy and during follow-up, patient medications, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCB), beta blockers, statin, glucocorticoids and immunosuppressant agents (Tacrolimus, Cyclosporine, Mycophenolate Mofetil and Cyclophosphamide), were recorded.
Patients were considered to have complete remission if proteinuria was less than 0.3 gm per day and creatinine was normal at 6 months after the biopsy. 13 Worsening renal function was defined as a doubling of the baseline serum creatinine at the last follow-up.
For the patients who underwent a second biopsy, the following data were collected: time between the first and second biopsy, reason for the second biopsy (increasing proteinuria, worsening serum creatinine, active lupus) and histological transformation to another class of LN in the second biopsy. The research was in compliance with the Declaration of Helsinki and was approved by the Ethics Committee of King Khaled University Hospital in Riyadh, Saudi Arabia.
Statistical analysis. Statistical analyses were carried out using the Statistical Package for the Social Science (SPSS version 24) software (Armonk, NY: IBM Corp.). Categorical variables are reported as absolute number and percent, and the continuous variables are given as the mean ± SD. We compared serum creatinine at baseline and the last follow-up visit for each patient. The endpoint for renal survival was defined as a doubling of serum creatinine or ESRD. P≤0.05 was considered significant.
Results. The study included 61 patients with SLE (59 female and 2 male) and class II LN. Twenty-nine patients were excluded due to missing data. The remaining 32 female patients had a mean age of 31.2 years at diagnosis with LN ( Table 1) . Hematuria with subnephrotic range proteinuria in 20 (62.5%) patients was the most frequent presentation, and 5 of these 20 had a gross hematuria. Subnephrotic-range proteinuria was seen in 8 patients, while 4 patients had a nephrotic range proteinuria ( Table 2) . Elevated blood pressure was observed in 7 patients (22%), and acute kidney injury (AKI) was also noted in 7 patients (22%). The median serum creatinine and proteinuria at diagnosis were 78 µmol/l (normal creatinine levels in women range from 60-110 µmol/L) and 0.8 gm per day (normal urinary protein excretion is <150 mg/24 hours), respectively.
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Anti-double-strand DNA antibodies were positive in 22 patients (68.75%), and low complements were observed in 11 patients (34.4%).
The prescribed medications were steroid monotherapy in 25 patients (78%), steroid and Mycophenolate Mofetil in 6 patients (18.8%), and steroid and Cyclophosphamide in one patient. The 25 patients treated with prednisolone alone had a median dosage of 60 mg per day (0.5-1 mg/kg), and complete remission at 6 months was seen in 23 patients (92%). Among those with abnormal serum creatinine at initial presentation, 4 patients had normalized serum creatinine, 2 had partial remission, and one had worsening renal function.
A second biopsy was carried out in 17 patients (53%). The reason for the repeated biopsy was an increase in proteinuria in 9 patients (53%), SLE flare with abnormal urine analysis in 5 patients (29.4%) and an increase in serum creatinine in 3 patients (17.6%). The median duration between the first and second biopsy was 5.5 years. The repeated biopsy showed transformation to other classes in 11 patients (64.7%): 5 patients transformed to class III, 4 patients transformed to class IV and 2 patients transformed to class VI ( Table 3) . After a median follow up of 8 years, renal function worsened in 2 patients.
Discussion. Although LN class II is considered a mild disease, one-fifth of patients present with serious disease. The most common clinical presentations of LN II are microscopic hematuria with subnephrotic range proteinuria and normal serum creatinine; 1, 3, 8 however, other reports have shown that those with initial presentation of LN class II might have nephrotic range proteinuria.
14 The heavy proteinuria possibly relates to podocytopathy, as the histological changes are not sufficiently severe to explain this degree of proteinuria. Our study also showed that patients with LN II may present with abnormal kidney function.
Although LN class II is considered a benign disease, our studies have shown that it is not always associated with favorable outcomes. 3, 10 The long-term outcomes depend on the initial clinical presentation, the response to therapy and the histological transformation (HT) to another class.
In our study, HT occurred in 11 patients (34.4%), which is comparable to results of other studies. Predicting those patients who will progress to other classes will help clinicians define the optimal time to begin therapy and increase remission rates. Collado et al 11 showed HT in 17 patients (41.4%) in a study of Argentine patients with LN class II. Pakozdi et al 8 reported a rate of HT of 63% in patients with LN class II. The frequency of HT in LN class II reinforces the concept that mesangial LN can be considered the beginning of a disease spectrum that starts in the mesangium and then progresses to involve other parts of the glomerulus. 15 Moreover, there is a discrepancy among the guidelines on the use of the immunosuppressing agents for Class II LN. 4, 6 In our study, we observed complete remission in 23 patients (92%) of those treated with prednisolone alone at a dosage of 0.5-1 mg/kg. Collado et al 11 reported that 70% of their patients responded to treatment with corticosteroids at a dosage of 0.5 to 1 mg/kg per day. A lower rate of remission was also observed in the study carried out by Collado et al, 11 in which 29% of the 34 patients with LN class II were in complete remission at one year. Clinicians may need to consider the initial clinical presentation of patients with class II LN. Patients with nephrotic range proteinuria or abnormal serum creatinine may need to be treated with more aggressive immunosuppressive therapy similar to those patients with class III or IV LN.
This study has several limitations. Retrospective methodologies are vulnerable to lost data and particularly to the loss of follow-up information. In addition, the study consists of a relatively small sample of LN biopsies. Despite these limitations, it is hypothesized that underestimating class II LN may have deleterious effects, specifically for patients with abnormal serum creatinine or advanced proteinuria. Individualizing treatment decisions and increasing immunosuppressive therapy among those patients who fail to reach complete remission on steroid monotherapy will be the best strategy until more evidence is available.
In conclusion, our study shows that class II LN carries a significant risk of histological transformation in subsequent kidney biopsies, which might affect the patient's outcome and prognosis. Daily steroid use as monotherapy may have potential therapeutic benefit; thus, could be considered for randomized controlled trial to prove its efficacy as the first line agent. Patients with ISN/RPS class II with AKI and/or nephrotic range proteinuria may warrant more aggressive immunosuppressive treatment similar to ISN/RPS III or IV. Larger prospective trials are needed to validate this strategy and identify those patients who are less likely to obtain remission.
